Vistagen Therapeutics Analyst Ratings
Vistagen Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 388.61% | Maxim Group | $30 → $30 | Maintains | Buy |
| 08/07/2023 | 388.61% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 46.58% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | -2.28% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | -2.28% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | -88.6% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 09/05/2023 | 388.61% | Maxim 集团 | 30 美元 → 30 美元 | 维护 | 购买 |
| 08/07/2023 | 388.61% | Maxim 集团 | → 30 美元 | 升级 | 持有 → 买入 |
| 07/26/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 07/22/2022 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 2021 年 5 月 20 日 | 46.58% | 贝尔德 | → 9 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2021 年 2 月 18 日 | -2.28% | 杰富瑞 | → 6 美元 | 启动覆盖开启 | → 购买 |
| 01/04/2021 | — | 威廉布莱尔 | 升级 | 市场表现 → 跑赢大盘 | |
| 2020 年 8 月 10 日 | -2.28% | 宙斯盾资本 | → 6 美元 | 启动覆盖开启 | → 购买 |
| 08/28/2019 | — | 威廉布莱尔 | 启动覆盖开启 | → 跑赢大盘 | |
| 07/22/2019 | -88.6% | 查丹资本 | 22 美元 → 0.7 美元 | 降级 | 买入 → 中性 |
What is the target price for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的目标价格是多少？
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023. The analyst firm set a price target for $30.00 expecting VTGN to rise to within 12 months (a possible 388.61% upside). 2 analyst firms have reported ratings in the last year.
Maxim集团于2023年9月5日公布了Vistagen Therapeutics（纳斯达克股票代码：VTGN）的最新目标股价。该分析公司将目标股价定为30.00美元，预计VTGN将在12个月内上涨至38.61％（可能上涨388.61％）。去年，有2家分析公司公布了评级。
What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?
分析师对Vistagen Therapeutics（VTGN）的最新评级是多少？
The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and Vistagen Therapeutics maintained their buy rating.
Vistagen Therapeutics（纳斯达克股票代码：VTGN）的最新分析师评级由Maxim集团提供，Vistagen Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Vistagen Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Vistagen Therapeutics的最新评级是在2023年9月5日提交的，因此你应该预计下一个评级将在2024年9月5日左右公布。
Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?
分析师对Vistagen Therapeutics（VTGN）的评级正确吗？
While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a maintained with a price target of $30.00 to $30.00. The current price Vistagen Therapeutics (VTGN) is trading at is $6.14, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Vistagen Therapeutics（VTGN）评级保持不变，目标股价为30.00美元至30.00美元。Vistagen Therapeutics（VTGN）目前的交易价格为6.14美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。